Organocatalytic Asymmetric Synthesis of SynVesT-1, a Synaptic Density Positron Emission Tomography Imaging Agent

Heterocyclic nonacetamide ligands are used as positron emission tomography (PET) imaging agents of the synaptic vesicle glycoprotein 2A (SV2A), with potential applications in the diagnosis of various neuropsychiatric diseases. To date, the main synthetic strategy to access these optically active compounds has involved the racemic synthesis of a late-stage intermediate followed by the separation of the enantiomers. Here, we describe the use of iminium organocatalysis for the asymmetric synthesis of SynVesT-1, an important PET imaging agent of SV2A. The key step involved the conjugate addition of nitromethane with a cinnamaldehyde in the presence of the Jørgensen–Hayashi catalyst using the Merck dual acid cocatalyst system. Pinnick-type oxidation and esterification of the adduct was then followed by chemoselective nitro group reduction and cyclization using nickel borate. N-Alkylation of the resulting lactam then completed the seven-step synthesis of SynVesT-1. This approach was amenable for the synthesis of an organotin analogue, which following copper(II)-mediated fluoro-destannylation allowed rapid access to [18F]SynVesT-1.

[1]  Xue-li Zheng,et al.  Selective Rhodium-Catalyzed Hydroformylation of Terminal Arylalkynes and Conjugated Enynes to (Poly)enals Enabled by a π-Acceptor Biphosphoramidite Ligand. , 2021, Organic letters.

[2]  Yiyun Huang,et al.  A metabolically stable PET tracer for imaging synaptic vesicle protein 2A: synthesis and preclinical characterization of [18F]SDM-16 , 2021, bioRxiv.

[3]  E. Salmon,et al.  The Rise of Synaptic Density PET Imaging , 2020, Molecules.

[4]  Yiyun Huang,et al.  Synthesis and Preclinical Evaluation of an 18F-Labeled Synaptic Vesicle Glycoprotein 2A PET Imaging Probe: [18F]SynVesT-2. , 2020, ACS chemical neuroscience.

[5]  Yiyun Huang,et al.  Synthesis and in vivo evaluation of [18F]UCB-J for PET imaging of synaptic vesicle glycoprotein 2A (SV2A) , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  Yiyun Huang,et al.  Synthesis and in Vivo Evaluation of a Novel PET Radiotracer for Imaging of Synaptic Vesicle Glycoprotein 2A (SV2A) in Nonhuman Primates. , 2018, ACS chemical neuroscience.

[7]  Christine M Sandiego,et al.  Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET Tracers , 2018, Molecular Imaging and Biology.

[8]  Allen F. Brooks,et al.  Automated synthesis of PET radiotracers by copper-mediated 18 F-fluorination of organoborons: Importance of the order of addition and competing protodeborylation. , 2018, Journal of labelled compounds & radiopharmaceuticals.

[9]  R. Mach,et al.  Consensus nomenclature rules for radiopharmaceutical chemistry - Setting the record straight. , 2017, Nuclear medicine and biology.

[10]  Biching Sang,et al.  Design, Synthesis, and Evaluation of the Highly Selective and Potent G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure. , 2017, Journal of medicinal chemistry.

[11]  R. Franzen,et al.  Puzzling Out Synaptic Vesicle 2 Family Members Functions , 2017, Front. Mol. Neurosci..

[12]  Shinji Tanaka,et al.  Copper-catalyzed Selective Oxygenation of Methyl and Benzyl Substituents in Pyridine with O2 , 2017 .

[13]  M. Lubberink,et al.  [(11)C]UCB-A, a novel PET tracer for synaptic vesicle protein 2A. , 2016, Nuclear medicine and biology.

[14]  Richard E Carson,et al.  Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain , 2016, The Journal of Nuclear Medicine.

[15]  O. Muzik,et al.  Radiosynthesis of (11)C-Levetiracetam: A Potential Marker for PET Imaging of SV2A Expression. , 2014, ACS medicinal chemistry letters.

[16]  X. Sauvage,et al.  Discovery of Heterocyclic Nonacetamide Synaptic Vesicle Protein 2A (SV2A) Ligands with Single‐Digit Nanomolar Potency: Opening Avenues towards the First SV2A Positron Emission Tomography (PET) Ligands , 2014, ChemMedChem.

[17]  Chang-Hua Ding,et al.  Regio- and enantioselective palladium-catalyzed allylic alkylation of nitromethane with monosubstituted allyl substrates: synthesis of (R)-rolipram and (R)-baclofen. , 2012, The Journal of organic chemistry.

[18]  Paul N. Devine,et al.  Asymmetric synthesis of telcagepant, a CGRP receptor antagonist for the treatment of migraine. , 2010, The Journal of organic chemistry.

[19]  D. MacMillan,et al.  The advent and development of organocatalysis , 2008, Nature.

[20]  Xinmiao Liang,et al.  An efficient enantioselective method for asymmetric Michael addition of nitroalkanes to alpha,beta-unsaturated aldehydes. , 2008, Chemical communications.

[21]  S. Mukherjee,et al.  Asymmetric enamine catalysis. , 2007, Chemical reviews.

[22]  Hao Li,et al.  Highly Enantioselective Organocatalytic Conjugate Addition of Nitromethane to α,β‐Unsaturated Aldehydes: Three‐Step Synthesis of Optically Active Baclofen , 2007 .

[23]  Y. Hayashi,et al.  Diphenylprolinol Silyl Ether as Catalyst of an Asymmetric, Catalytic, and Direct Michael Reaction of Nitroalkanes with α,β-Unsaturated Aldehydes , 2007 .

[24]  P. Pihko,et al.  Iminium catalysis. , 2007, Chemical reviews.

[25]  Y. Hayashi,et al.  Diphenylprolinol silyl ethers as efficient organocatalysts for the asymmetric Michael reaction of aldehydes and nitroalkenes. , 2005, Angewandte Chemie.

[26]  K. Jørgensen,et al.  Enantioselective Organocatalyzed α Sulfenylation of Aldehydes , 2005 .

[27]  P. Camps,et al.  Synthesis of both enantiomers of baclofen using (R)- and (S)-N-phenylpantolactam as chiral auxiliaries , 2004 .

[28]  K. Nocka,et al.  The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[29]  E. Dalcanale,et al.  Selective oxidation of aldehydes to carboxylic acids with sodium chlorite-hydrogen peroxide , 1986 .

[30]  S. Sharma,et al.  Synthesis and stability of 2-methyl-2,4-diaza- and 2-methyl-2,5-diaza-indene (2-methyl-pyrrolo(3,4-b)pyridine and -pyrrolo(3,4-c)pyridine). , 1972, Journal of the Chemical Society. Perkin transactions 1.